Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
25 juin 2022 04h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
Immunocore Appoints Siddharth Kaul to its Board of Directors
09 juin 2022 07h45 HE
|
Immunocore Holdings Limited
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR)...
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
08 juin 2022 07h00 HE
|
Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
03 juin 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...
Immunocore to present at upcoming investor conferences
01 juin 2022 16h30 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 1 June 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a...
NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
26 mai 2022 18h00 HE
|
NovalGen Ltd.
- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
11 mai 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...
Immunocore to present at the 21st Annual Needham Healthcare Conference
07 avr. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 21st Annual Needham Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 7 April 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
04 avr. 2022 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
03 mars 2022 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...